Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website. We are a privately held clinical-stage biopharmaceutical company. Our mission is to discover and develop novel CNS drugs as ion modulators and neuroprotectors.

Research & Drug Development

Pipeline

Newron's clinical pipeline is supported by a broad portfolio of early stage proprietary compounds generated by our ion channel discovery platform.

The Company has two products in clinical trials:

  • Safinamide, a unique molecule with multiple mechanisms of action, in Phase III for the treatment of Parkinson's disease and in Phase II for Restless Leg Syndrome.
  • Ralfinamide, an innovative tretament for neuropathic pain in Phase II clinical development

    •